NCT02393612View on ClinicalTrials.gov

Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Peripheral Arterial Disease

Interventions

DRUG

DP-R202

Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks

DRUG

Anplag tab

Anplag tab 100mg is administrated to patients with PAD for 12 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alvogen Korea

INDUSTRY